Skip to main content
. 2017 Mar 9;109(7):djw317. doi: 10.1093/jnci/djw317

Figure 4.

Figure 4.

Comparative analysis of tumors with higher levels of progesterone receptor isoform A (PR-A) than progesterone receptor isoform B (PR-B; PRA-H) and tumors with higher levels of PR-B than PR-A (PRB-H) gene expression signatures and the prognostic value of predicted PR isoforms across two independent breast cancer data sets. A) Heatmap of PRA-H- and PRB-H-associated gene expression signatures among 586 luminal-like and PR+ primary invasive breast carcinomas obtained from the The Cancer Genome Atlas (TCGA)–Breast Invasive Carcinoma project. Black lines at the bottom indicate the predicted PR isoforms. B) Relapse-free survival curves of the predicted PRA-H and PRB-H cases among the TCGA data set. C) Heatmap of PRA-H- and PRB-H-associated gene expression signatures among 355 luminal-like primary invasive breast carcinomas obtained from a data set reported by Yau et al. in 2010. Black lines at the bottom indicate the predicted PR isoforms. D) Distant metastasis-free survival curves of the predicted PRA-H and PRB-H cases among the same data set. P values were calculated using two-sided log-rank test. PR = progesterone receptor; PR-A = PR isoform A; PR-B = PR isoform B; PRA-H = tumors with higher levels of PR-A than PR-B; PRB-H = tumors with higher levels of PR-B than PR-A.